Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/222825
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

AuthorsOcio, Enrique M. CSIC ORCID ; Motlló, Cristina; Rodríguez-Otero, Paula; Martínez-López, Joaquín; Cejalvo, Mª José; Martín-Sánchez, Jesús; Bladé, Joan; García‐Malo, Mª Dolores; Dourdil, Mª Victoria; García-Mateo, Aránzazu; Arriba, Felipe de; García-Sanz, Ramón; Rubia, Javier de la; Oriol, Albert; Lahuerta, Juan José; San Miguel, Jesús F. CSIC ORCID; Mateos, Maria Victoria
Issue Date2020
PublisherWiley-VCH
CitationBritish Journal of Haematology: (2020)
AbstractThis phase I/II trial evaluated the combination of the kinesin spindle protein inhibitor filanesib with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) patients. Forty‐seven RRMM patients with a median of three prior lines (2–8) and 94% refractory to lenalidomide were included: 14 in phase I and 33 in phase II. The recommended dose was 1·25 mg/m2 of filanesib on days 1, 2, 15, 16, with pomalidomide 4 mg on days 1–21 and dexamethasone 40 mg weekly. The defined threshold for success was achieved, with 18 out of 31 patients obtaining at least minor response (MR) in the phase II. In the global population, 51% of patients achieved at least partial response (PR) and 60% ≥MR, resulting in a median progression‐free survival (mPFS) of seven months and overall survival (OS) of 19 months. The main toxicity was haematological. Importantly, patients with low serum levels of alpha 1‐acid glycoprotein (AAG) at baseline (<800 mg/l) had a superior response (overall response rate of 62% vs. 17%; P = 0·04), which also translated into a longer mPFS (9 vs. 2 months; P = 0·014). In summary, filanesib with pomalidomide and dexamethasone is active in RRMM although with significant haematological toxicity. Most importantly, high levels of AAG can identify patients unlikely to respond to this strategy.
Publisher version (URL)https://doi.org/10.1111/bjh.16788
URIhttp://hdl.handle.net/10261/222825
DOI10.1111/bjh.16788
ISSN0007-1048
E-ISSN1365-2141
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.